Introduction: Paragangliomas are rare neuroendocrine neoplasms that arise from neural crest cells, and are associated with increased expression of angiogenic growth factors. There have been isolated case reports describing potential efficacy with Sunitinib, a tyrosine kinase inhibitor.
Aim(s): Here we report a case demonstrating an impressive clinical response to treatment with Sunitinib.
Materials and methods: A 53-year-old female initially presented with back pain and leg weakness secondary to a malignant lesion in L4. Staging investigations also revealed bilateral cervical masses and pulmonary metastases. She underwent surgical decompression and histology revealed a well-differentiated neuroendocrine tumor in keeping with a diagnosis of bilateral cervical paraganglioma. She was unsuitable for debulking surgery, and MIBG and chemotherapy were considered to have a low probability of benefit. She was therefore commenced on Sunitinib 50mg for four weeks followed by two weeks off treatment.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dr Olga Oikonomidou
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Teresa Gagliano
Introduction: Pheochromocitomas and Paragangliomas (PCs/PGLs) are rare neuroendocrine tumors arising from the adrenal medulla and extra-adrenal ganglia. Around 30-40% of these neoplasms are genetically determined. PCs/PGLs arising from the sympathetic chain can synthesize bioactive amines leading to typical syndromes, in contrast to parasympathetic PGLs that are mainly non-secretory.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu
Introduction: Sunitinib has shown activity against pancreatic neuroendocrine tumors(NEN) in a global phase III clinical trial.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Chen Jie
Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Emilio Bajetta
Introduction: Intracardiac PGLs are extremely rare neuroendocrine tumors. There are few reported series in literature, indicating surgery as the most effective treatment modality.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: MD Maura Rossi